Belgium’s Novadip Biosciences raises €10.4 million to fund pivotal clinical trial and unlock EIB loan tranche
Novadip Biosciences, a Belgian late-stage clinical BioTech company specialising in regenerative medicine, has closed a €10.4 million (roughly $12 million) convertible financing round. The round was led by US-based New Science Ventures, with participation from a syndicate of Novadip’s existing backers, including Fund+, Wallonie Entreprendre, VIVES Fund, ORSA Tech, Sambrinvest, Noshaq and…
Belgian biotech Novadip Biosciences has raised €10.4 million in convertible financing to support a pivotal Phase 3 clinical trial for its regenerative medicine product, NVD003. Led by US venture firm New Science Ventures, the round brings total convertible funding to €20 million since June 2025. Novadip, founded in 2013, develops a proprietary 3M³ platform that uses a patient's own stem cells in a 3D extracellular matrix to regenerate bone.
The NVD003 trial, currently underway in the US and EU, aims to treat congenital pseudarthrosis of the tibia (CPT), a rare pediatric bone condition. Successful completion of the trial and FDA approval could bring a Rare Pediatric Disease Priority Review Voucher worth over $100 million. The funding will also help Novadip prepare a US Biologics License Application and pursue strategic partnerships.
Written by urgent.news from EU-Startups's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
